RD13-02
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for RD13-02, covering 2024-11-22 to 2024-12-13. Get the full timeline:
Most recent: Clinical Trial Update: RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies [Phase 1]